Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

USA and South Korea, Pennsylvania


A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes

Study summary:

Objectives 1. To assess the safety, tolerability and initial anti-diabetic activity of MLR-1023 in subjects with uncontrolled mild to moderate type 2 diabetes mellitus 2. To evaluate the pharmacokinetics of MLR-1023 and the major metabolite, MLR-1023-M1 following 28 days of repeat dosing Design and Outcomes The study is a randomized, double blind, placebo-controlled, parallel group study of MLR-1023 in adult subjects with uncontrolled type 2 diabetes mellitus who are on diet and exercise therapy. A subset of subjects per dose group will have additional samples analyzed to measure signs of MLR-1023.


Inclusion Criteria: 1. Diagnosed with uncontrolled T2DM who have received diet and exercise therapy for at least 3 months prior to screening, aged ≥ 18 - ≤ 75 years 2. Females must be post-menopausal, unable to conceive, or test negative for pregnancy via blood test and use barrier contraception 3. BMI ranging from ≥ 20 to ≤ 40 kg/m2 4. Fasting plasma glucose values of up to 240 mg/dL at screening, after wash-out (visit 2) and after placebo run-in (visit 3) 5. (i) naïve or (ii) currently using and discontinued metformin or (iii) no prior exposure to anti-diabetic agents other than metformin ≥ 6 months prior to screening Exclusion Criteria: 1. History of Type 1 diabetes 2. History of more than 1 episode of severe hypoglycemia within 6 months prior to screening, or a current diagnosis of hypoglycemia unawareness. 3. Hospitalizations or Emergency room visits that would impact patient safety or data interpretation: 1. Due to poor glucose control in the 6 months prior to screening or 2. Any bariatric surgical procedures for weight loss. 4. Significant change of body weight (>10%) in the 3 months before screening 5. Proliferative retinopathy or maculopathy within the 6 months before screening or requiring acute treatment, or severe neuropathy



Primary Contact:

Study Director
Melior Pharmaceuticals I & Bukwang Pharm. Co., Ltd.
Melior Pharmaceuticals I & Bukwang Pharm. Co., Ltd.

Backup Contact:


Location Contact:

USA and South Korea, Pennsylvania
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.